Review



nacubactam  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress nacubactam
    Nacubactam, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nacubactam/product/MedChemExpress
    Average 93 stars, based on 4 article reviews
    nacubactam - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    nacubactam  (MedChemExpress)
    93
    MedChemExpress nacubactam
    Nacubactam, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nacubactam/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    nacubactam - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    nacubactam op0595 fpi-1459 rg6080 ro7079901  (Meiji Seika Pharma Co Ltd)
    90
    Meiji Seika Pharma Co Ltd nacubactam op0595 fpi-1459 rg6080 ro7079901
    Global pipeline of small-molecule antibiotics with reported clinical trials
    Nacubactam Op0595 Fpi 1459 Rg6080 Ro7079901, supplied by Meiji Seika Pharma Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nacubactam op0595 fpi-1459 rg6080 ro7079901/product/Meiji Seika Pharma Co Ltd
    Average 90 stars, based on 1 article reviews
    nacubactam op0595 fpi-1459 rg6080 ro7079901 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    nacubactam  (Keio University Press Inc)
    90
    Keio University Press Inc nacubactam
    Global pipeline of small-molecule antibiotics with reported clinical trials
    Nacubactam, supplied by Keio University Press Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nacubactam/product/Keio University Press Inc
    Average 90 stars, based on 1 article reviews
    nacubactam - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    aztreonam/nacubactam  (MBL Life science)
    90
    MBL Life science aztreonam/nacubactam
    Global pipeline of small-molecule antibiotics with reported clinical trials
    Aztreonam/Nacubactam, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aztreonam/nacubactam/product/MBL Life science
    Average 90 stars, based on 1 article reviews
    aztreonam/nacubactam - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    nacubactam  (Wockhardt limited)
    90
    Wockhardt limited nacubactam
    Global pipeline of small-molecule antibiotics with reported clinical trials
    Nacubactam, supplied by Wockhardt limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nacubactam/product/Wockhardt limited
    Average 90 stars, based on 1 article reviews
    nacubactam - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    nacubactam op0595 fpi-1459 rg6080 ro7079901 iv  (Meiji Seika Pharma Co Ltd)
    90
    Meiji Seika Pharma Co Ltd nacubactam op0595 fpi-1459 rg6080 ro7079901 iv
    β-Lactam/β-lactamase inhibitor (BL/BLI) combinations in clinical trials or submitted for regulatory approval (structures in Figs. <xref ref-type= 11 – 13 )" width="250" height="auto" />
    Nacubactam Op0595 Fpi 1459 Rg6080 Ro7079901 Iv, supplied by Meiji Seika Pharma Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nacubactam op0595 fpi-1459 rg6080 ro7079901 iv/product/Meiji Seika Pharma Co Ltd
    Average 90 stars, based on 1 article reviews
    nacubactam op0595 fpi-1459 rg6080 ro7079901 iv - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    aztreonam/nacubactam  (Becton Dickinson)
    90
    Becton Dickinson aztreonam/nacubactam
    Characteristics of the strains used
    Aztreonam/Nacubactam, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aztreonam/nacubactam/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    aztreonam/nacubactam - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Global pipeline of small-molecule antibiotics with reported clinical trials

    Journal: Drugs

    Article Title: Antibacterials with Novel Chemical Scaffolds in Clinical Development

    doi: 10.1007/s40265-024-02137-x

    Figure Lengend Snippet: Global pipeline of small-molecule antibiotics with reported clinical trials

    Article Snippet: Nacubactam (OP0595, FPI-1459, RG6080, RO7079901) + meropenem , DBO BLI + carbapenem , Meiji Seika, Roche , Cell wall (PBP) , NCT02134834 (I), NCT02975388 (I), NCT03182504 (I), NCT02972255 (I), NCT03174795 (I) , [ ] .

    Techniques: Infection, Disruption, DNA Synthesis, Binding Assay, Membrane, Polymer

    β-Lactam/β-lactamase inhibitor (BL/BLI) combinations in clinical trials or submitted for regulatory approval (structures in Figs. <xref ref-type= 11 – 13 )" width="100%" height="100%">

    Journal: The Journal of Antibiotics

    Article Title: Antibiotics in the clinical pipeline as of December 2022

    doi: 10.1038/s41429-023-00629-8

    Figure Lengend Snippet: β-Lactam/β-lactamase inhibitor (BL/BLI) combinations in clinical trials or submitted for regulatory approval (structures in Figs. 11 – 13 )

    Article Snippet: Nacubactam ( 65 ) (OP0595, FPI-1459, RG6080, RO7079901; IV) is a DBO-type BLI [ – ], which was developed by Meiji Seika Pharma (Tokyo, Japan).

    Techniques: Clinical Proteomics, Full Display Name, CtB Assay

    Characteristics of the strains used

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: Characteristics of the strains used

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques:

    Estimation of fT >MICi . (a) Simulated free plasma nacubactam PK profile; (b) calculated aztreonam MIC i transition after administration of nacubactam based on the dose–response curve; (c) free plasma aztreonam PK profile (solid orange line) and aztreonam MIC i transition (blue dashed line) were superimposed. The % fT >MICi is the percentage of time that the free plasma aztreonam concentration exceeded the MIC i . This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: Estimation of fT >MICi . (a) Simulated free plasma nacubactam PK profile; (b) calculated aztreonam MIC i transition after administration of nacubactam based on the dose–response curve; (c) free plasma aztreonam PK profile (solid orange line) and aztreonam MIC i transition (blue dashed line) were superimposed. The % fT >MICi is the percentage of time that the free plasma aztreonam concentration exceeded the MIC i . This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques: Concentration Assay

    MIC curve between the aztreonam MIC and the nacubactam concentration ( n = 3). (a) NDM-1-positive K. pneumoniae ATCC BAA-2473; (b) IMP-6-positive K. pneumoniae MSC 21664; (c) OXA-48-positive K. pneumoniae MSC 21444.

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: MIC curve between the aztreonam MIC and the nacubactam concentration ( n = 3). (a) NDM-1-positive K. pneumoniae ATCC BAA-2473; (b) IMP-6-positive K. pneumoniae MSC 21664; (c) OXA-48-positive K. pneumoniae MSC 21444.

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques: Concentration Assay

    PK profiles of nacubactam (a) and aztreonam (b) in neutropenic mice (mean ± SD, n = 3).

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: PK profiles of nacubactam (a) and aztreonam (b) in neutropenic mice (mean ± SD, n = 3).

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques:

    In vivo dose-fractionation study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with NDM-1-positive K. pneumoniae ATCC BAA-2473 (mean ± SD, n = 3). Aztreonam was administered every 2 h, and nacubactam was administered with variable frequency: every 2 h, every 4 h and every 8 h.

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: In vivo dose-fractionation study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with NDM-1-positive K. pneumoniae ATCC BAA-2473 (mean ± SD, n = 3). Aztreonam was administered every 2 h, and nacubactam was administered with variable frequency: every 2 h, every 4 h and every 8 h.

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques: In Vivo, Fractionation, Infection

    In vivo dose-ranging study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with IMP-6-positive K. pneumoniae MSC 21664 (a) and OXA-48-positive K. pneumoniae MSC 21444 (b) (mean ± SD, n = 3). Both nacubactam and aztreonam were administered every 2 h.

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: In vivo dose-ranging study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with IMP-6-positive K. pneumoniae MSC 21664 (a) and OXA-48-positive K. pneumoniae MSC 21444 (b) (mean ± SD, n = 3). Both nacubactam and aztreonam were administered every 2 h.

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques: In Vivo, Infection

    PK/PD analysis and target fT >MICi values of aztreonam with/without nacubactam.

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: PK/PD analysis and target fT >MICi values of aztreonam with/without nacubactam.

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques:

    PK/PD analysis based on fT > C T with optimal C T values of nacubactam (a), f AUC 24 of nacubactam (b), and fC max of nacubactam (c).

    Journal: Journal of Antimicrobial Chemotherapy

    Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    doi: 10.1093/jac/dkad033

    Figure Lengend Snippet: PK/PD analysis based on fT > C T with optimal C T values of nacubactam (a), f AUC 24 of nacubactam (b), and fC max of nacubactam (c).

    Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

    Techniques: